Functions and underlying mechanisms of IncRNA HOTAIR in cancer chemotherapy resistance

Chunming Zhu¹, Xia Wang², Yuan Wang ³ and Kefeng Wang ² ⁴

© The Author(s) 2022

Chemotherapy has been one of the most important treatments for advanced cancer in recent decades. Although the sensitivity rate of initial chemotherapy is high, patients with chemotherapy resistant tumors, experience tumor recurrence. In recent years, many studies have shown that homeobox transcript antisense intergenic RNA (HOTAIR) is involved in many pathological processes including carcinogenesis. The abnormal regulation of a variety of cell functions by HOTAIR, such as apoptosis, the cell cycle, epithelial-mesenchymal transition, autophagy, self-renewal, and metabolism, is associated with chemotherapy resistance. Therefore, there is an urgent need to understand the biology and mechanism underlying the role of HOTAIR in tumor behavior and its potential as a biomarker for predicting the effect of chemotherapy. In this manuscript, we review the mechanisms underlying HOTAIR-related drug resistance and discuss the limitations of current knowledge and propose potential future directions.

Cell Death Discovery (2022) 8:383; https://doi.org/10.1038/s41420-022-01174-3

FACTS

- Cancer has become a major threat to human health, but there is no effective way to stop its progress.
- Chemotherapy plays an important role in controlling tumor growth, but chemotherapy resistance is still a difficult problem to be solved.
- HOTAIR has been shown to be abnormally expressed in a variety of cancers and is associated with poor prognosis.
- With the emergence of tumor resistance, HOTAIR has also been confirmed to be involved in chemotherapy resistance of tumors.

OPEN QUESTIONS

- What is the specific mechanism of HOTAIR's involvement in tumor chemotherapy resistance?
- How to reduce drug resistance by inhibiting the expression of HOTAIR in clinic?

INTRODUCTION

Long non-coding RNAs (lncRNAs) are non-coding RNAs with a length of over 200 nucleotides [1]. lncRNAs are mainly transcribed by RNA polymerase II from different regions of the entire genome. Growing evidence shows that lncRNAs are involved in a variety of carcinogenic processes, such as tumor proliferation, invasion, and metastasis [2–4]. The role of IncRNAs in tumorigenesis and tumor progression has been widely investigated. However, studies of the role of IncRNAs in cancer resistance to chemotherapy are still at a nascent stage [5].

Homeobox transcript antisense intergenic RNA (HOTAIR) is an important polyadenylated and spliced lncRNA, containing 6 exons and 2158 nucleotides [6]. HOTAIR is transcribed from the antisense strand of the HOXC gene, which is located between HOXC11 and HOXC12 on chromosome 12q13.13 (Fig. 1) [7]. Abnormal overexpression of HOTAIR in cancer was first identified in breast cancer (BC) and has been associated with metastasis and poor survival [8]. Elevated expression of HOTAIR was found to induce genome-wide retargeting of polycomb repressive complex 2 (PRC2), leading to increase metastasis and invasion in BC cells [8]. Since then, HOTAIR has been attracting attention in the field of cancer.

Chemotherapy plays an important role in controlling tumor growth and can increase the survival time of patients [9]. Several studies have shown that chemotherapy can significantly reduce the mortality rate of patients with advanced tumors and those who cannot undergo surgery [10, 11]. Despite the effectiveness of chemotherapy, the acquired chemotherapeutic resistance is a huge challenge to cancer treatment. Chemotherapy resistance can lead to tumor recurrence and increase patient mortality. The mechanisms underlying the development of resistance in cancer cells involve: (1) inhibition of cell apoptosis and protection of damaged cells, (2) avoidance of cell cycle checkpoints, (3) enhancement of epithelial-mesenchymal transition (EMT), (4) reconstitution of the cell autophagy system, (5) enhancement of self-renewal ability, (6) remodeling the repair ability of DNA, (7) alteration of drug metabolism and transport, which affects the
pharmacokinetics in cancer cells, (8) and modulation of the tumor microenvironment (TME) (Fig. 2) [12–14]. In this review, we discuss the research progress on the relationship between HOTAIR and cancer chemotherapy resistance.

**HOTAIR BIOGENESIS AND GENERAL FUNCTIONS**

HOTAIR, first identified by Rinn et al. in 2007 [6], can inhibit the transcription of 40 kb at the HOXD site. HOTAIR is a key regulator of transcriptional silencing and chromatin remodeling. HOTAIR interacts with some vital epigenetic regulators, such as PRC2 and lysine-specific histone demethylase 1 A (LSD1) to regulate gene silencing [15, 16]. The PRC2 complex contains four main subunits, namely, SUZ12, EED, EZH2, and R8AP46/48, and interacts with a fragment at the 5’ end of HOTAIR [17]. Silencing of HOTAIR could activate the transcriptional repression of the HOXD site on chromosome 2 by reducing the tri-methylation of H3 lysine 27 trimethylation (H3K27me3), which is the feature of gene silencing modulated by EZH2, a member of the PRC2 family [18]. Another mechanism underlying the mode of interaction of HOTAIR with PRC2 has been proposed, according to which PRC2 interacts with short repeats of successive guanines in HOTAIR rather than with specific domains (Fig. 3) [19]. Recent studies revealed that RNA G-quadruplexes (G4s) at the 5’ end of HOTAIR mediated the reciprocal interaction with PRC2 [20]. RNA G4s are made by stacking two or more connected square planes of four guanines and are involved in many important cellular processes and the pathogenesis of various diseases, such as cancer [21]. Besides PRC2, the LSD1 complex is another important partner of HOTAIR, which interacts with a fragment at the 3’ end of HOTAIR (Fig. 3) [16]. The LSD1 complex consists of LSD1, REST, and CoREST, which inhibit gene expression by decreasing the tri-methylation of histone H3 Lys 4 (H3K4me3). In addition, recent studies have shown that HOTAIR influences miRNA-mediated inhibition of...
target gene expression through competitive binding with miRNA [22, 23]. Furthermore, HOTAIR alters gene expression by pairing with translation factors or ribosomal bases to control translation. In conclusion, HOTAIR functions as a scaffold to assemble the inhibitory complex composed of PRC2 and LSD1, thereby silencing its target genes through H3K27me3 (PRC2 activity) and H3K4me3 (LSD1 activity), respectively.

HOTAIR is found not only in humans, but also in mice and rats. However, it does not exist in non-mammalian vertebrates [24]. The sequence similarity between mouse HOTAIR and human HOTAIR is about 58%, while it is about 50% in rat HOTAIR [25, 26]. Therefore, HOTAIR in mammalian vertebrates is conservative. The human HOTAIR gene has 6 exons, whereas the rat and mouse HOTAIR gene has only 5 exons because exon 2 is not present [26]. There are two domains in exon 6 of rat and mouse HOTAIR, called domains A and B. Domain B is responsible for the interaction between HOTAIR and plenty of proteins [26]. However, the physiological function of domain A remains unclear.

HOTAIR is a vital modulator of chromatin dynamics. It acts on multiple genetic sites and modulates their expression [27]. HOTAIR interacts with RNA, DNA, and proteins to participate in a variety of cellular functions. During mammalian embryogenesis, HOTAIR is expressed in the forelimb and wrist, hindlimb bud and posterior trunk, and genital bud and tail [28]. In humans, HOTAIR is highly concentrated in the skin and reproductive system, mainly involving endometrium, prostate and testis [28]. HOTAIR can down-regulate osteogenic genes BMP2 and ALPL, indicating that HOTAIR has a negative regulatory role in the process of osteogenesis [29]. HOTAIR is involved in cell senescence by interacting with E3 ubiquitin ligases [30]. HOTAIR also participates in cell proliferation by regulating the expression of cell cycle-related proteins and kinases [28].

**MECHANISMS MEDIATING HOTAIR-RELATED CHEMOTHERAPY RESISTANCE IN CANCER**

HOTAIR regulates cell apoptosis and cell cycle

The ability of cancer cells to respond to chemotherapy drugs is thought to be due to their ability to undergo apoptosis. Drug-induced apoptosis is not only modulated by an
upregulation of pro-apoptotic factors but also regulated by cell survival factors [31]. Recent studies revealed that HOTAIR is involved in the modulation of the apoptotic pathway in cancer cells, which may be related to chemotherapy resistance (Table 1). For example, a study showed that HOTAIR suppression promoted apoptosis and doxorubicin sensitivity in acute myeloid leukemia (AML). Furthermore, an investigation of the mechanism indicated that HOTAIR conferred multidrug resistance (MDR) to AML cells by modulating the expression of the AKT/Notch1 and P21 signaling pathways [32]. Another research group reported that HOTAIR inhibited PTEN expression in a manner dependent on DNMT3b upregulation, which resulted in doxorubicin resistance in AML [33]. In addition, downregulation of HOTAIR played a vital role in enhancing the acquired resistance to imatinib via PI3K/AKT signaling in chronic myelogenous leukemia (CML) [34]. Furthermore, the PI3K/AKT signaling pathway was found to be involved in HOTAIR-mediated cell apoptosis and chemotherapy resistance in BC and gastric cancer (GC) [35, 36]. Similar results have been widely reported in other digestive system tumors. The study by Zhang et al. [37] revealed that targeting HOTAIR sensitized esophageal cancer cells to 5-fluorouracil (5-FU) chemotherapy through the down-regulation of methylenetetrahydrofolate reductase expression. In hepatocellular carcinoma (HCC), downregulation of HOTAIR weakened Taxol resistance through the Wnt/β-catenin and Akt phosphorylation pathways via antagonizing miR-34a [38]. In pancreatic cancer, high HOTAIR expression expedited cell resistance to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through modulation of TRAIL receptor death receptor 5 expression [39]. Recently, it was reported that HOTAIR expression in non-small cell lung cancer (NSCLC) was dramatically higher than that in adjacent tissues and that high HOTAIR expression was associated with shortened overall patient survival. Small interfering RNA targeting HOTAIR (si-HOTAIR) reversed the acquired resistance to imatinib via PI3K/AKT signaling in chronic myelogenous leukemia (CML) [34]. Furthermore, the PI3K/AKT signaling pathway was found to be involved in HOTAIR-mediated cell apoptosis and chemotherapy resistance in BC and gastric cancer (GC) [35, 36]. Similarly, the study by Fang et al. [51] revealed that suppression of HOTAIR expression prolonged the S phase and increased cell sensitivity to DDP, adriamycin (ADM), and etoposide (VP-16) by modulating HOXA1 methylation in small cell lung cancer (SCLC). The collection and analysis of bioinformatic data has attracted increasing attention. Liu et al. [52] proposed that HOTAIR was related to cell cycle pathways using Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of The Cancer Genome Atlas public database. The underlying molecular mechanisms indicated that HOTAIR heightened cell resistance to gefitinib by accelerating the progression of the cell cycle from the G1 to S phase by modulating the Rb-E2F pathway. In another study, a traditional Chinese medicine formula Xiaoji decoction (XJD) was demonstrated to suppress cell proliferation and induce cell arrest at the G2/M phase in NSCLC. Mechanism analysis showed that XJD reinforced the effect of the antineoplastic drug gefitinib through downregulation of EP4 induced by HOTAIR silencing [53]. In GC, upregulation of HOTAIR facilitated G1 to S phase transition and led to DDP resistance; HOTAIR performed its function by sponging miR-126 to promote PI3K/AKT/MPR1 signaling [54]. Another study showed that abnormally overexpressed HOTAIR stimulated cell proliferation and cell cycle transition to the S phase. Upregulation of HOTAIR increased doxorubicin and paclitaxel (PTX) resistance by suppressing the miR-217/GPC5/PTPN14 pathway [55]. In ovarian cancer (OC), HOTAIR enhanced PTX resistance through upregulation of CHEK1 expression. In contrast, si-HOTAIR, which could be used as a therapeutic target for OC, accelerated cell cycle arrest at the G2/M phase and boosted cell sensitivity to PTX [56]. The study by Xiang et al. [57] demonstrated that polyphenyl I (PPI), a main component extracted from Rhizoma Paridis saponins, played an anticancer role in prostate cancer. Further investigation into the mechanisms indicated that PPI suppressed cell growth at the S phase through downregulation of the expression of HOTAIR and its downstream targets DNMT1 and EZH2. In multiple cancers, HOTAIR expression was associated with shortened overall patient survival. In addition, the overexpression of HOTAIR was found to be related to the acquisition of resistance to chemotherapeutic regimens and the occurrence of multidrug resistance (MDR) in cancer cells, which is conducive to cancer progression and chemotherapeutic resistance. Furthermore, studies have demonstrated that HOTAIR could be a potential therapeutic target for overcoming the resistance of cancer cells to chemotherapy by silencing or downregulating its expression.
Table 3. HOTAIR enhances EMT.

| Cancer type             | Expression | Related drugs | Target       | Related genes or pathway | References |
|------------------------|------------|---------------|--------------|--------------------------|------------|
| Lung cancer            | upregulation | gefitinib     | /            | Rb-E2F                   | [62]       |
| Hepatocellular cancer  | upregulation | sorafenib     | miR-217      | Vimentin and E-cadherin  | [63]       |
| Gastric cancer         | upregulation | cisplatin, Adriamycin, Mitomycin, and 5-fluoroura | miR-17-5p | PTEN                     | [64]       |
| Breast cancer          | upregulation | trastuzumab   | /            | MEK/MAPK and PI3K/ AKT/ mTOR | [65]       |
| Prostate cancer        | upregulation | paclitaxel    | /            | Bcl-2 and Bax            | [66]       |
| Glioblastoma           | upregulation | temozolomide  | miR-519a-3p  | RRM1                     | [67]       |

Table 4. HOTAIR enhances autophagy.

| Cancer type             | Expression | Related drugs | Target | Related genes or pathway | References |
|------------------------|------------|---------------|--------|--------------------------|------------|
| Lung cancer            | upregulation | crizotinib    | /      | ULK1                     | [72]       |
| Oral cavity carcinoma  | upregulation | cisplatin     | /      | Autophagy-related gene    | [73]       |
| Gastrointestinal stromal tumor | upregulation | imatinib    | miR-130a | ATG2B                   | [74]       |
| Endometrial cancer     | upregulation | cisplatin     | /      | MDR, Beclin-1, and P-gp  | [74]       |
| Ovarian cancer         | upregulation | cisplatin     | /      | ATG7                     | [76]       |
| Renal cancer           | upregulation | sunitinib     | miR-17-5p | Beclin1                 | [77]       |

myeloma (MM), downregulation of HOTAIR inhibited cell viability by inducing cell cycle arrest at the G0/G1 phase. Functional assays validated that HOTAIR enhanced cell activity and chemotherapy resistance to dexamethasone (DEX) via the JAK2/STAT3 pathway. Cui et al. [58] validated that HOTAIR enhanced cell activity and chemotherapy resistance to DEX via the JAK2/STAT3 pathway. 

Taken together, the above data show that si-HOTAIR induces cell cycle arrest and decreases chemotherapy resistance in many cancers. Two important apical kinases, ataxia telangietasia and Rad3-related and ataxia telangietasia-mutated, are involved in the regulation of the relevant signal pathway through downstream signal relay proteins and effector proteins, such as CHK1, CHK2, MDM2, P53, BRCA1, PIK3, and CDC25 [59, 60]. Thus, it could be considered as a diagnostic biomarker and therapeutic target in cancer.

HOTAIR enhances EMT

EMT refers to the transformation of epithelial cells into cells with mesenchymal phenotypes. EMT plays important roles in embryonic development, chronic inflammation, tissue remodeling, organ fibrosis, as well as cancer metastasis [61].

Several studies indicate that HOTAIR takes part in the regulation of EMT in cancer cells, affecting chemotherapy resistance [62]. It has been reported that the HOTAIR expression level was associated with chemotherapy resistance to epidermal growth factor receptor tyrosine kinase inhibitors through activating EMT in NSCLC. Uregulation of HOTAIR retarded gefitinib sensitivity in NSCLC cells, which served as a predictive biomarker for gefitinib resistance [62]. Another group reported that sorafenib resistance was accelerated in cells with abnormally overexpressed HOTAIR in HCC. An in-depth molecular mechanism analysis showed that si-HOTAIR enhanced sorafenib sensitivity by decreasing the Vimentin level and increasing the E-cadherin level by upregulating miR-217, which indicated that EMT may participate in HOTAIR-induced chemotherapy resistance [63]. The study by Jia et al. [64] showed that HOTAIR overexpression expedited the EMT process by regulating the miR-17-5p/PTEN pathway in GC. Therefore, anti-HOTAIR treatment boosted the sensitivity to chemotherapeutic drugs. In another study, suppression of HOTAIR expression influenced the expression of EMT-related genes in BC.

HOTAIR downregulation using siRNA weakened trastuzumab resistance through activating the MEK/MAPK and PI3K/AKT/mTOR pathways [65]. In prostate cancer, propofol strengthened PTX sensitivity by regulating HOTAIR-mediated EMT [66]. In GBM, HOTAIR knockdown suppressed tumor growth, migration, and invasion and EMT, whereas exosomal HOTAIR accelerated TMZ resistance by the mTR-519a-3p/RRM1 pathway [67].

Overall, emerging evidence shows that this process is driven by some EMT-inducing transcription factors (EMT-TFs), such as SNAI1/2, ZEB1/2, and TWIST1/2 [68]. EMT-TFs have been found to change chemotherapy resistance through several molecular mechanisms [69]. These data support the conclusion that HOTAIR enhances EMT and decreases chemotherapeutic sensitivity in various cancers.

HOTAIR enhances autophagy

Autophagy is the process in which autophagosomes, consisting of cytoplasmic proteins or organelles enclosed into vesicles, fuse with lysosomes to form autophagy lysosomes, delivering their contents for degradation, to realize the metabolic needs of cells and the renewal of some organelles [70]. In cancer, autophagy is a double-edged sword, depending on the cellular environment and the characteristics of the tumors, including tumor stage, grade, type, and genetic relationships [71].

Recently, a series of studies revealed that HOTAIR plays a vital role in autophagy-mediated chemotherapeutic sensitivity in human cancers (Table 4). In NSCLC, HOTAIR silencing attenuated drug resistance to crizotinib through suppressing autophagy by inhibiting the ULK1 pathway [72]. Soon after, a study reported that HOTAIR knockdown inhibited autophagy by downregulating autophagy-related genes and increased drug sensitivity to DDP in oral squamous cell carcinoma [73]. The study by Zhang et al. [74] demonstrated that HOTAIR targeted miR-130a, the ATG2B inhibitor, to promote drug resistance to imatinib by elevating autophagy levels in gastrointestinal stromal tumors. Similar results indicated that HOTAIR modulated cisplatin resistance through the modulation of autophagy by affecting MDR, Beclin-1, and P-glycoprotein (P-gp) expression in endometrial cancer [75]. Another research group found that HOTAIR was overexpressed...
in OC and that ATG7 was the downstream gene of HOTAIR. Downregulation of HOTAIR enhanced DDP sensitivity by suppressing DDP-induced cell autophagy [76]. In renal cancer, HOTAIR targeted miR-17-5p to stimulate Beclin1-mediated autophagy, thereby increasing sunitinib resistance [77].

Taken together, under normal or mild stress conditions, mild autophagy is conducive to cell survival, whereas excessive autophagy results in cell death [78]. The process of autophagy involves multiple steps, each of which is regulated by a set of core autophagy related proteins and transcription factors [79]. Therefore, the regulation of chemotherapeutic sensitivity by intervening with the regulatory factors involved in the autophagy process has become a promising new approach for cancer treatment. These data confirm that HOTAIR could enhance autophagy and decrease chemotherapeutic sensitivity in human tumors, providing the foundation for novel and promising antitumor therapy approaches.

**HOTAIR enhances the self-renewal ability of cancer stem cells**

Cancer stem cells (CSCs) are cells with self-renewal abilities that lead to tumorigenesis [80, 81]. The abnormal self-renewal mechanism of CSCs leads to tumor cell proliferation and tumor tissue enlargement.

Recent studies have shown that IncRNAs regulate the stem cell properties of cancer cells (Table 5). Liu et al. [82] found that HOTAIR upregulation enhanced NSCLC cell resistance to DDP. Overexpression of HOTAIR increased the expression of CSC-related biomarkers and was correlated with Klf4 expression, which could be used as a promising therapeutic target. A year later, another group found that gemcitabine may induce HOTAIR as a tumor promoter. HOTAIR promotes PACN-1 CSC self-renewal ability, growth, and migration by inhibiting the chemosensitivity of PACN-1 CSCs, supporting its potential as a new therapeutic target for pancreatic cancer [83]. In BC, HOTAIR was found to be a vital regulator of the self-renewal ability of CSCs, which occurred partly through modulation of the miR-34a/50x2/p53 signal pathway [84]. In prostate cancer, HOTAIR elevated the quantity of CSCs by activating the STAT3 signal pathway. Investigation of the mechanisms showed that HOTAIR sponged MiR-206-mediated suppression of TBX3 levels and enhanced DDP drug resistance, providing a novel biomarker for OC treatment [85]. In another study, the HOTAIR level was upregulated in OC CSCs, which stimulated their colony-forming and sphere-forming abilities. Interrupting the HOTAIR-EZH2 interaction and DNA methylation is likely to boost chemosensitivity and restrain cancer recurrence [87].

Thus, several important signaling pathways have been shown to be involved in the self-renewal of CSCs, including the Bmi1, Notch, Wnt, and Hedgehog signaling pathways [88–91]. HOTAIR enhances the self-renewal ability of CSCs and plays a vital role in cancer chemosensitivity and recurrence.

**HOTAIR interferes with the DNA repair pathway**

The DNA in every cell of the human body is suffered tens of thousands damage each day. DNA repair is a cellular response to DNA damage aiming to restore the DNA structure and function. DNA repair protects the genome from damage and mutation and is therefore important for cell survival [92]. Fortunately, cells contain a variety of DNA repair mechanisms, including: (1) nucleotide excision repair (NER), which removes large amounts of DNA adducts; (2) base excision repair (BER), which removes damaged bases; (3) mismatch repair (MMR), which recognizes base damage and incorporation errors; (4) cross-linking repair (ICL), which removes interstrand cross-links; (5) nonhomologous end joining (NHEJ) and homologous recombination (HR), which repairs DNA backbone damage; (6) DNA damage response (DDR), which deals with multi-step complex DNA damage repair.

Qian et al. [93] revealed that overexpression of HOTAIR promoted the expression of DDR factors, including DNA-protein kinases, Ku protein (Ku70 and Ku80), and ATM. Alternatively, these signaling molecules in the double-strand break repair pathway can be blocked by EZH2. Another research group demonstrated that DNA damage induced HOTAIR expression in a p53-dependent manner, indicating that HOTAIR involved in complex DDR. Therefore, HOTAIR might mediate the resistance of oral squamous cells to doxorubicin and irradiation [68]. Similar results indicated that HOTAIR silencing sensitized BCA cells to radiation, induced DNA damage, suggesting that HOTAIR may be a novel therapeutic target for BCA [94]. In addition, Gao et al. [95] reported that HOTAIR was positively correlated with the degree of DNA damage, which indicated that HOTAIR may be involved in the modulation of DNA damage induced by PAHs exposure. Gupta et al. [8] demonstrated that enhanced expression of HOTAIR induced genome-wide retargeting of PRC2, resulting in altered H3K27me3 gene expression, and increased cancer invasion and metastasis in a PRC2-dependent manner during BC progression. Similar results indicated that the HOTAIR level was associated with genome-wide reprogramming of PRC2 function and that HOTAIR upregulation could be a key factor in the progression of colorectal cancer (CRC) metastasis [96]. Recently, HOTAIR was found to affect chemotherapeutic resistance by interfering with DNA repair (Table 6).

Liu et al. [50] reported that HOTAIR recruited EZH2 to transcriptionally inhibit the expression of p21 (WAF1/CIP1) by modifying H3K27me3, thereby triggering DDP resistance by inhibiting p21-dependent DNA repair suppression in NSCLC. Another study

| Table 5. | HOTAIR enhances the self-renewal ability of cancer stem cells. |
| --- | --- | --- | --- | --- | --- |
| Cancer type | Expression | Related drugs | Target | Related genes or pathway | References |
| Lung cancer | upregulation | cisplatin | / | Klf4 | [82] |
| Pancreatic cancer | upregulation | gemcitabine | / | / | [83] |
| Prostatic cancer | upregulation | docetaxel | mir-590-5p | STAT3 | [85] |
| Ovarian cancer | upregulation | cisplatin | mir-206 | TBX3 | [86] |
| Ovarian cancer | upregulation | platinum/paclitaxel | / | / | [87] |

| Table 6. | HOTAIR participates in interfering with DNA repair pathway. |
| --- | --- | --- | --- | --- | --- |
| Cancer type | Expression | Related drugs | Target | Related genes or pathway | References |
| Oral cavity carcinoma | upregulation | doxorubicin | / | / | [68] |
| Lung cancer | upregulation | cisplatin | / | P21 | [50] |
| Ovarian cancer | upregulation | platinum | / | NF-κB | [97] |
showed that HOTAIR modulated the activation of NF-κB by reducing the NF-κB inhibitor IκBα in OC. Furthermore, they demonstrated that HOTAIR played a key role in platinum chemotherapy resistance and cellular senescence by inducing prolonged NF-κB activation and expression of NF-κB target genes during DNA damage [97].

Together, these studies demonstrate that HOTAIR participates in chemotherapy resistance by interfering with the DNA repair pathway.

**HOTAIR affects the drug efflux pump**

Scientists had demonstrated that a major factor in the development of MDR in cancer cells was the reduction of drug accumulation. Approximately 40 years ago, Juliano et al. [98] discovered that P-gp mediates the active flow of chemotherapeutic drugs from cancer cells, resulting in pleiotropic drug cross-resistance.

A multitude of data has shown that HOTAIR causes chemotherapy resistance by modulating ABC transporters to affect the drug efflux pump (Table 7). In GC, the evidence demonstrated that the high expression of HOTAIR was associated with DDP resistance. HOTAIR could directly bind and inhibit the active expression of miR-126, thereby activating the PI3K/AKT/MRP1 pathway [54]. A year later, similar results indicated that downregulation of HOTAIR might enhance the sensitivity of CML cells to imatinib through the PI3K/AKT/MRP1 pathway [34]. In HCC, Zhou et al. [99] reported that HOTAIR silencing impaired STAT3 activity and multi-drug resistant protein 1 (MDR1, ABCB1) expression and decreased chemotherapy resistance to DDP. Therefore, HOTAIR could become a new potential therapeutic target for the reversal of MDR in HCC. Subsequent studies showed that TGF-β1 was involved in a novel MDR mechanism by upregulating BCRP and P-gp through the SMAD4/HOTAIR/miR-145 pathway in HCC [100]. In NSCLC, an in-depth study revealed that si-HOTAIR enhanced the sensitivity of cells to DDP by inhibiting the expression levels of MRP1 and MDR1, as well as the Wnt signaling pathway [40].

These results confirm that HOTAIR is involved in chemotherapy resistance by affecting the drug efflux pump in human tumors.

**HOTAIR influences the TME**

The TME refers to the close relationship between the occurrence, growth, and metastasis of tumors and the internal and external environment of tumor cells. It is a hypoxic and acidic environment, with high osmotic pressure, containing microbiota, inflammatory factors, tumor-associated macrophages, extracellular matrix and molecules, and cancer-associated fibroblasts.

Several studies have revealed that HOTAIR influences drug resistance in an altered TME (Table 8). In 2017, a peptide nucleic acid (PNA)-mediated approach was discovered to block and inhibit the activity of the HOTAIR-EZH2 interaction, which resensitized resistant OC to platinum. Mechanically, PNAs were conjugated to pH-low insertion peptide (pHLIP) to facilitate the delivery of anti-HOTAIR effects to an acidic (pH about 6) TME. The pHLIP-PNA complex suppressed the activity of HOTAIR and decreased tumor formation, suggesting a new approach for the treatment of solid tumor drug resistance [101].

Overall, these data indicate that HOTAIR influences chemoresistance in an altered TME.

**THERAPEUTIC POTENTIAL OF HOTAIR IN CANCER**

A large number of studies have shown the effect of HOTAIR on the occurrence, progression, and metastasis of multiple tumors. Therefore, treatment strategies based on HOTAIR, including RNA interference (RNAi), small molecule inhibitors and antisense oligonucleotides (ASOs), have attracted wide attention. Gupta et al. [8] adopted RNAi technology to target HOTAIR and create HOTAIR knockout. Similarly, Lennox et al. [102] found that both RNAi and ASOs effectively inhibited HOTAIR. In addition, Bhan et al. [103] invented a synthetic small interfering nucleotide DNA complementary to the HOTAIR transcript to suppress the expression of HOTAIR.

Moreover, there are some inhibitors that suppress HOTAIR function without altering its expression level. For instance, Li et al. [104] discovered a small molecule compound, AC1Q3QWB (AQB), functioning as a HOTAIR-EZH2 inhibitor to block PRC2 recruitment. One year later, Shi et al. [105] demonstrated that the combination of AQB and palbociclib led to a higher inhibition of growth and metastasis than that obtained using the single drug in glioma cells with high HOTAIR expression. Ozes et al. [101] revealed that overexpression of HOTAIR blocked the binding of HOTAIR to EZH2, thereby decreasing tumor invasion and increasing chemotherapy sensitivity in breast and ovarian cancer cells. Therefore, screening a larger library of natural and synthetic compounds to identify compounds that target the interaction between HOTAIR and PRC2 complexes could be an alternative strategy for targeting HOTAIR/EZH2-dependent cancers.

The exact molecular mechanisms by which HOTAIR is involved in cancer progression are more intricate than originally thought and have not yet been applied in the clinic. More research is needed to further understand the role of HOTAIR in the pathogenesis of human cancers.

**CONCLUSIONS AND PROSPECTS**

Chemotherapy is a cancer treatment that involves the use of chemical drugs to prevent the proliferation, invasion, and metastasis of cancer cells and to finally kill them. It is a systemic treatment and together with surgery and radiation constitutes the three major cancer treatment types. However, tumor cells can

---

**Table 7.** HOTAIR participates in affecting the drug efflux pump.

| Cancer type       | Expression | Related drugs | Target     | Related genes or pathway | References |
|-------------------|-----------|---------------|------------|---------------------------|------------|
| Gastric cancer    | upregulation | cisplatin     | miR-126   | PI3K/AKT/MRP1             | [54]       |
| Leukemia          | upregulation | platinum      | /          | PI3K/AKT/MRP1             | [34]       |
| Hepatocellular cancer | upregulation | cisplatin     | /          | MDR1                      | [99]       |
| Hepatocellular cancer | upregulation | imatinib      | miR-145   | P-gp and BCRP             | [100]      |
| Lung cancer       | upregulation | cisplatin     | /          | MRP1, MDR1 and Wnt        | [40]       |

**Table 8.** HOTAIR influences tumor microenvironment.

| Cancer type | Expression | Related drugs | Target | Related genes or pathway | References |
|-------------|------------|---------------|--------|---------------------------|------------|
| Ovarian cancer | upregulation | platinum      | /      | /                         | [101]       |
develop resistance to chemotherapeutic drugs, resulting in a significant reduction in the chemotherapeutic effect of the drugs. Therefore, chemotherapy resistance is a problem that needs to be urgently solved.

Recently, IncRNAs have been widely recognized as an important biological regulator of the tumor progression process. Furthermore, some IncRNAs, including HOTAIR, have been found to be involved in chemotherapy resistance [3, 32, 106, 107]. According to the literature, HOTAIR-induced MDR has been shown to increase drug resistance and decrease drug sensitivity in a variety of cancers. In this review, we explored the different mechanisms by which HOTAIR induces drug resistance in various tumors and showed that HOTAIR could confer resistance to multiple anticancer drugs, such as doxorubicin, ADM, imatinib, DDP, 5-FU, taxol, progesterone, TMZ, VP-16, gefitinib, PTX, DEX, sorafenib, mitomycin, cis, trastuzumab, crizotinib, sunitinib, gemcitabine, docetaxel, platinum, PTX, and oxaliplatin. Furthermore, a series of miRNAs were involved in HOTAIR-mediated chemoresistance resistance, such as miR-34a, miR-106a-5p, miR-125, miR-217, miR-17-5p, miR-519a-3p, miR-130a, miR-590-5p, miR-206, and miR-145. Moreover, the Wnt/β-catenin and PI3K/Akt signaling pathways were two important mediators of HOTAIR chemoresistance. In addition, we found that most studies used RNA-seq to screen IncRNAs with different expression patterns between resistant and non-resistant cell lines to explore the mechanisms of chemotherapy resistance, and targeting these differentially expressed IncRNAs might contribute to the elimination of chemotherapy resistance.

According to literature reports, we can see that the current research on the role of HOTAIR in tumor chemotherapy resistance is still in its infancy. There are still some challenges to be solved. First, studies of HOTAIR in cancer chemotherapy resistance are limited to a few classic drugs and a few cancer types. More drugs and cancer types need to be investigated. Second, HOTAIR polymorphisms and their relationship with chemotherapy response have not been evaluated in a large cohort of patients. Therefore, future studies should be performed to fill this research gap. Third, although many studies revealed that HOTAIR was associated with chemotherapy resistance, few studies investigated how drug resistance can be reduced by inhibiting HOTAIR expression in clinical practice. Further clinical studies may provide a new direction for exploring the mechanisms of HOTAIR-related drug resistance.

In conclusion, HOTAIR is closely involved in tumor development and associated with chemotherapy resistance. We summarized the various mechanisms by which HOTAIR leads to tumor resistance and conclude that HOTAIR may play an important role in cancer therapy in the future. Therefore, further exploration in this field could provide additional approaches to the treatment of tumor drug resistance.

REFERENCES

1. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81:145–66.
2. Wang K, Jin W, Song Y, Fei X. LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-3p and promotes proliferation and invasion in renal cell carcinoma. Mol Cancer. 2017;16:166.
3. Wang MY, Mohan D, Yuan Z, Hu H, Zhao Z, Yang R, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9:1149.
4. Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu Z, et al. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett. 2015;359:75–83.
5. Deng H, Zhang J, Ji S, Guo Z, He C, Ding L, et al. Role of long non-coding RNA in tumor drug resistance. Tumour Biol. 2016;37:1123–31.
6. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007;129:1311–23.
7. Woo CJ, Kingston RE. HOTAIR lifts noncoding RNAs to new levels. Cell. 2007;129:1257–9.
8. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464:1071–6.
9. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363–85.
10. Wakeem E, Acuna SA, Leight NB, Giuliani ME, Finlayson SRG, Varghese TK, et al. Sorcery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival. Lung Cancer. 2017;109:78–88.
11. Ashdown ML, Robinson AF, Yatomi-Clarke SL, Ashdown ML, Allison A, Abbott D, et al. Chemotherapy for late-stage cancer patients: meta-analysis of complete response rates. F1000Res. 2015;4:2322.
12. Mansoos B, Mohammadi A, Davoodian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7:339–48.
13. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Prac. 2005;14:35–48.
14. Nunes T, Hamdan D, Leboeuf C, Bouchtaoui MEI, Gupahan G, Nguyen TT, et al. Targeting cancer stem cells to overcome chemoresistance. Int J Mol Sci. 2018;19:4036.
15. Bhan A, Mandal SS. LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer. Biochim Biophys Acta. 2015;1856:151–64.
16. Majello B, Gorini F, Saccà CD, Amente S. Expanding the role of the histone lysine-specific demethylase LSD1 in cancer. Biosci Rep. 2019;11:324.
17. Marqueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011;469:343–9.
18. Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. ChemMedChem 2014;9:1932–56.
19. Wang X, Goodrich KJ, Gooding AR, Naem H, Archer S, Paucké R, et al. Targeting of polycomb repressive complex 2 to RNA by short repeats of consecutive guanines. Mol Cell. 2017;65:1056–67.
20. Long Y, Bolanos B, Gong L, Liu W, Goodrich KJ, Yang X, et al. Conserved RNA-binding specificity of polycomb repressive complex 2 is achieved by dispersed amino acid patches in EZH2. Elife 2017;6:e31558.
21. Fay MM, Lyons SM, Ivanov P. Quadruplexes in biology: principles and molecular mechanisms. J Mol Biol. 2017;429:2127–47.
22. Zhou Y, Wang Y, Lin M, Wu D, Zhao M. LncRNA HOTAIR promotes proliferation and inhibits apoptosis by sponging miR-214-3p in HPV16 positive cervical cancer cells. Cancer Cell Int. 2021;21:400.
23. Jia S, Xie D, Jin H, Fan S, Wang X, Xu L. Long non-coding RNA HOTAIR as a competitive endogenous RNA to sponge miR-206 to promote colorectal cancer progression by activating CCL2. J Cancer. 2020;11:4431–41.
24. Wu Y, Liu J, Zheng Y, You L, Huang D, Liu T. Suppressed expression of long non-coding RNA HOTAIR inhibits proliferation and tumourigenicity of renal carcinoma cells. Tumour Biol. 2014;35:11887–94.
25. Schorderet P, Doboule D. Structural and functional differences in the long non-coding RNA hotair in mouse and human. PLoS Genet. 2011;7:e1002071.
26. He S, Liu S, Zhu H. The structure, sequence and evolutionary features of HOTAIR in mammals. BMC Evol Biol. 2011;11:102.
27. Tan SK, Pastori C, Penas C, Komotar RJ, Ivan ME, Wahlestedt C, et al. Serum long non-coding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. Mol Cancer. 2018;17:24.
28. Mozdarani H, Ezzatizadeh V, Parvaneh RR. The emerging role of the long non-coding RNA HOTAIR in breast cancer development and treatment. J Transl Med. 2020;18:152.
29. Carron K, Dyo J, Patel V, Sasik R, Mohammad SA, Hardiman G, et al. The long non-coding HOTAIR is modulated by cyclic stretch and WNT/beta-CATENIN in human aortic valve cells and is a novel repressor of calcification genes. PLoS One. 2014;9:e96577.
30. Yoon JH, Abdelmohsen K, Kim J, Yang X, Martinelle JD, Tominaga-Yamanaka K, et al. Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination. Nat Commun. 2013;4:2939.
31. Fraser M, Leung B, Ivanov P. Quadruplexes in biology: principles and molecular mechanisms. J Mol Biol. 2017;429:2127–47.
32. Zhou W, Xu S, Chen X, Wang C. HOTAIR suppresses PTEN via DNMT3b and c demethylase LSD1 in cancer. Cancers (Basel). 2019;11:324.
33. Lil M, Wang Y, Xu Y, Lu Q. Overexpression of LncRNA-HOTAIR promotes chemoresistance in acute myeloid leukemia. Hematology 2021;26:170–8.
34. Zhou W, Li Q, Tang S, Li M, Feng A, Qin L, et al. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. Hematology 2017;22:208–16.
35. Li Z, Qian J, Li J, Zhu C. Knockdown of IncRNA-HOTAIR downregulates the drug resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med. 2019;18:435–42.

C. Zhu et al.
36. Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107:2620–9.

37. Zhang S, Zheng F, Zhang L, Huang Z, Huang X, Pan Z, et al. LncRNA HOTAIR-mediated MTFRH methylation inhibits S-fluorouracil sensitivity in esophageal cancer cells. J Exp Clin Cancer Res. 2020;39:93.

38. Duan Y, Chen J, Yang Y, Qu Z, Lu Y, Sun D. LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a. Biosci Rep. 2020;40:BSR20201627.

39. Yang S, Xu F, Zhou T, Zhao X, McDonald JM, Chen Y. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand. J Biol Chem. 2017;292:10390–7.

40. Guo F, Cao Z, Guo H, Li S. The action mechanism of IncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway. Exp Ther Med. 2018;15:4885–9.

41. Fang S, Shen Y, Chen B, Wu Y, Jia L, Li Y, et al. H3K27me3 induces multidrug resistance in small cell lung cancer by affecting HOXA1 DNA methylation via regulation of the IncRNA HOTAIR. Ann Transl Med. 2018;6:440.

42. Guo J, Dou D, Zhang T, Wang B. HOTAIR Promotes Cisplatin Resistance of Osteosarcoma Cells by Regulating Cell Proliferation, Invasion, and Apoptosis via miR-106a-5p/STAT3 Axis. Cell Transpl. 2020;29:63689720948447.

43. Chi S, Liu Y, Zhou X, Feng D, Xiao A, Li W, et al. Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B. Cancer Chemother Pharmacol. 2019;83:277–87.

44. Zhang J, Chen G, Gao Y, Liang H. HOTAIR/miR-125 axis-mediated Hexokinase 2 expression promotes chemoresistance in human glioblastoma. J Cell Mol Med. 2020;24:5707–17.

45. Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2001;2:REVIEWS3009.

46. Krammer PH. CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol. 1999;71:163–210.

47. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, et al. Viral relatives: IAPs and other BIRPs. Genome Biol. 2001;2:REVIEWS3009.

48. Moosavi MA, Haghi A, Rahmati M, Taniguchi H, Mocan A, Echeverria J, et al. Phytochemicals as potent modulators of autophagy for cancer therapy. Cancer Genomics 2021;43:807–13.

49. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2020;39:131.

50. Liu Z, Sun M, Zhu J, Zhang C, Zhang M, Song Y, et al. The contrary functions of lncRNA HOTAIR/ miR-106a-5p/STAT3 Axis. Cell Transpl. 2020;29:963689720948447.

51. Kondo Y, Kanazawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005;5:726–34.

52. Yang J, Jiang C, Yang Y, Guo L, Huang J, Liu X, et al. Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochem Biophys Res Commun. 2018;497:1003–10.

53. Sun M, Zhu J, Zhang C, Zhang M, Song Y, et al. RNA interference of long noncoding RNA HOTAIR suppresses apoptosis and promotes sensitivity to cisplatin in oral squamous cell carcinoma. J Oral Pathol Med. 2018;47:930–7.

54. Jia J, Zhan D, Li J, Li Z, Li H, Qian J. The contrary functions of IncRNA HOTAIR in oral squamous cell carcinoma Tca8113 cells and its associated biological behavior. Am J Transl Res. 2016;8:4726–34.

55. Fullgrabe JN, Baker D, Dijke PT, Dam H. Epithelial-mesenchymal-transition–inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene 2018;37:6195–211.

56. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for antianticancer therapy. Nat Rev Clin Oncol. 2011;8:328–39.

57. Kondo Y, Kanazawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005;5:726–34.

58. Yang J, Jiang C, Yang Y, Guo L, Huang J, Liu X, et al. Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochem Biophys Res Commun. 2018;497:1003–10.

59. Sun M, Zhu J, Zhang C, Zhang M, Song Y, et al. Autophagy regulated by IncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells. Biotechnol Lett. 2017;39:1477–84.

60. Zhong J, Chen K, Tang Y, Luan X, Zheng X, Liu X, et al. LncRNA-HOTAIR activates autophagy and promotes the imatinib resistance of gastrointestinal stromal tumor cells through a mechanism involving the miR-130a/ATG2B pathway. Cell Death Dis. 2012;11:1221.

61. Sun M, Zhu J, Zhang C, Zhang M, Song Y, et al. Autophagy regulated by IncRNA HOTAIR contributes to the cisplatin-induced resistance in endometrial cancer cells. Biotechnol Lett. 2017;39:1477–84.

62. Wang Q, Li X, Ren S, Su C, Li C, Li W, et al. HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition. Lung Cancer. 2020;147:99–105.

63. Tang X, Zhang W, Ye Y, Li H, Cheng L, Zhang M, et al. LncRNA HOTAIR contributes to sorafenib resistance through suppressing miR-217 in hepatic carcinoma. Biomed Res Int. 2020;2020:9515071.

64. Jia J, Zhan D, Li J, Liu Z, et al. The contrary functions of IncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqiuqizheng injection on chemosensitivity of gastric cancer cells. J Cell Mol Med. 2019;23:656–69.

65. Chen T, Liu Z, Zeng W, Huang T. Down-regulation of long non-coding RNA HOTAIR sensitizes breast cancer to trastuzumab. Sci Rep. 2019;9:19881.

66. Yang X, Qin J, Gong C, Yang J. Propofol enhanced the cell sensitivity to paclitaxel (PTX) in prostate cancer (PC) through modulation of HOTAIR. Genomics Genomes 2021;43:807–14.

67. Yuan Z, Yang Z, Li W, Wu A, Su Z, Jiang B. Exosomatic-mediated transfer of long noncoding RNA HOTAIR regulates temozolomide resistance by miR-519a-3p/RRM1 axis in glioblastoma. Cancer Biother Radiopharm. 2020;37:515–28.

68. Liu P, Li W, Zhang C, Feng L, Huang H, Liu C, et al. Expression of long non-coding RNA HOTAIR in oral squamous cell carcinoma Tca8113 cells and its associated biological behavior. Am J Transl Res. 2016;8:4726–34.

69. C. Zhu et al.
Kong Y, Ai C, Dong F, Xia X, Zhao X, Yang C, et al. Targeting of BMI-1 with PTC-209 inhibits glioblastoma development. Cell Cycle. 2018;17:1199–211.

Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70:709–18.

Won HY, Lee JY, Shin DH, Park J, Nam J, Kim H, et al. Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway. FASEB J. 2012;26:5002–13.

Po A, Ferretti E, Miele E, Smaele ED, Paganelli A, Canettieri G, et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J. 2010;29:2646–58.

Wang J, Lindahl T. Maintenance of Genome Stability. Genomics Proteom Bioinforma. 2016;14:119–21.

Qian L, Fei Q, Zhang H, Qiu M, Zhang B, Wang Q, et al. IncRNA HOTAIR promotes DNA repair and radiosensitivity of breast cancer via EZH2. DNA Cell Biol. 2020;39:2166–73.

Hu X, Ding D, Zhang J, Cui J. Knockdown of IncRNA HOTAIR sensitizes breast cancer cells to ionizing radiation through activating miR-218. Biosci Rep. 2019;39:BSR20181038.

Gao C, He Z, Li J, Li X, Bai Q, Zhang Z, et al. Specific long non-coding RNAs response to occupational PANS exposure in coke oven workers. Toxicol Rep. 2016;3:160–6.

Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto S, Sudo T, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71:6320–6.

Ozes AR, Miller DF, Ozes ON, Fang F, Liu Y, Matei D, et al. NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene 2016;35:5350–61.

Liu Y, Ren Y, Wang Y, Tan Y, Wang Q, Cai J, et al. A compound AC1Q3QWB regulates polycomb-dependent recruitment of PRC2 and enhances cancer therapy of DZNep. Theranostics 2019;9:4608–23.

Shi J, Lv S, Wu M, Wang X, Deng Y, Li Y, et al. HOTAIR-EZH2 inhibitor AC1Q3QWB upregulates CWF19L1 and enhances cell cycle inhibition of CDK4/6 inhibitor palbociclib in glioma. Clin Transl Med. 2020;10:182–8.

Hu Y, Yu Y, You S, Li K, Tong X, Chen S, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16:174.

Du P, Zhao H, Peng R, Liu Q, Yuan J, Peng G, et al. LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biochim Biophys Acta. 2017;1867:265–76.

Diana K, Pagel S, Schmitt L, von Knebel Doeberitz M. The lncRNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71:6320–6.

Oeses AR, Miller DF, Oeses ON, Fang F, Liu Y, Matei D, et al. NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene 2016;35:5350–61.

Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152–62.

Zhou J, Cheng D, He X, Meng Z, Ye H, Chen R. Knockdown of long non-coding RNA HOTAIR sensitizes hepatocellular carcinoma cell to cisplatin by suppressing the STAT3/ABCB1 signaling pathway. Oncol Lett. 2017;14:7986–92.

Kong J, Qiu Y, Li Y, Zhang H, Wang W. TGF-β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis. Biopharm Drug Dispos. 2019;40:70–80.

Ozes AR, Wang Y, Zong X, Fang F, Pilrose J, Nephew KP. Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Sci Rep. 2017;7:894.

Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res. 2016;44:863–77.

Bhan A, Hassian I, Ansari KI, Kasiri S, Bashyal A, Mandal SS. Antisense transcript long noncoding RNA (IncRNA) HOTAIR is transcriptionally induced by estradiol. J Mol Biol. 2013;425:3707–22.

Li Y, Ren Y, Wang Y, Tan Y, Wang Q, Cai J, et al. A compound AC1Q3QWB selectively disrupts HOTAIR-mediated recruitment of PRC2 and enhances cancer therapy of DZNep. Theranostics 2019;9:4608–23.

Shi J, Lv S, Wu M, Wang X, Deng Y, Li Y, et al. HOTAIR-EZH2 inhibitor AC1Q3QWB upregulates CWF19L1 and enhances cell cycle inhibition of CDK4/6 inhibitor palbociclib in glioma. Clin Transl Med. 2020;10:182–8.

Hu Y, Yu Y, You S, Li K, Tong X, Chen S, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2017;16:174.

Du P, Zhao H, Peng R, Liu Q, Yuan J, Peng G, et al. LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biochim Biophys Acta. 2017;1867:265–76.

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

ACKNOWLEDGEMENTS

We thank Yun Cui from the Department of Urology, National Urological Cancer Center, Peking University First Hospital and Institute of Urology for helping us prepare the manuscript.

AUTHOR CONTRIBUTIONS

KW and YW conceived the review, KW, CZ, and XW wrote the manuscript. All authors read and approved the final manuscript.

FUNDING

This work was supported by National Natural Science Foundation of China (Grant No. 82072835) to KW, Key Research and Development Joint Program of Liaoning Province (Grant No. 2020JH 2/10300139) to KW, National Science Foundation of Liaoning Province (Grant No. 2019-M5-360) to KW, Shenyang Science and Technology Bureau Plan Projects (Grant No. 20-205-4-076) to KW, 345 Talent Project of Shengjing Hospital of China Medical University (Grant No. M0366) to KW, Outstanding Scientific Fund of Shengjing Hospital to KW.

COMPETING INTERESTS

The authors declare no competing interests.

CONSENT FOR PUBLICATION

Written consent for publication was obtained from all the participants.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Yuan Wang or Kefeng Wang.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022